A phase 1 study of SCB-808 for the treatment of rheumatoid arthritis and other autoimmune diseases in china.
Phase of Trial: Phase I
Latest Information Update: 28 Dec 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Clover Biopharmaceuticals
- 28 Dec 2017 New trial record
- 22 Dec 2017 According to a Clover Biopharmaceuticals media release, company has received Clinical Trial Application (CTA) approval from the Chinese Food and Drug Administration (CFDA) to conduct the clinical trials for SCB-808 in China. This trial is expect to initiate in mid 2018.